Tango Therapeutics, Inc.
TNGX
$25.60
-$0.05-0.20%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -100.00% | 363.61% | -83.99% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -100.00% | 363.61% | -83.99% |
| Cost of Revenue | 13.39% | -7.98% | -5.41% | -7.36% | -15.13% |
| Gross Profit | -25.56% | -8.00% | -7.65% | 206.19% | -57.76% |
| SG&A Expenses | 99.15% | 32.71% | -11.97% | -20.48% | 5.27% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 35.42% | 1.77% | -7.02% | -10.67% | -10.68% |
| Operating Income | -45.93% | -14.67% | -2.33% | 142.80% | -38.63% |
| Income Before Tax | -42.56% | -14.23% | -3.14% | 154.53% | -52.31% |
| Income Tax Expenses | -97.14% | -97.06% | -212.24% | -118.52% | -46.15% |
| Earnings from Continuing Operations | -42.44% | -14.14% | -2.86% | 154.46% | -52.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -42.44% | -14.14% | -2.86% | 154.46% | -52.06% |
| EBIT | -45.93% | -14.67% | -2.33% | 142.80% | -38.63% |
| EBITDA | -47.14% | -15.27% | -2.72% | 145.35% | -39.50% |
| EPS Basic | -5.04% | 12.31% | 15.03% | 153.24% | -49.00% |
| Normalized Basic EPS | -5.15% | 11.51% | 10.02% | 153.31% | -49.22% |
| EPS Diluted | -5.04% | 12.31% | 15.03% | 148.15% | -49.00% |
| Normalized Diluted EPS | -5.15% | 11.51% | 10.02% | 150.21% | -49.22% |
| Average Basic Shares Outstanding | 35.58% | 30.17% | 21.08% | 2.27% | 2.06% |
| Average Diluted Shares Outstanding | 35.58% | 30.17% | 21.08% | 8.55% | 2.06% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |